SCHEMBL5871684

SCHEMBL5871684

CC(=O)N1CCC(CNC(=O)Cc2ccc3c(OC(=O)C(=O)Oc4cn(C5CCN(C(F)Cc6ccccc6)CC5)c5cc(CC(=O)NCC6CCN(C(C)=O)CC6)ccc45)cn(C4CCN(C(F)Cc5ccccc5)CC4)c3c2)CC1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTSD P07339 3/20 0.37
YAP1 P46937 2/20 0.35
TACR1 P25103 1/20 0.34
NPC1 O15118 1/20 0.34
CCNE1 P24864 1/20 0.32
CDK2 P24941 1/20 0.32
FAAH O00519 5/20 0.32
ACHE P22303 5/20 0.32
BCHE P06276 3/20 0.32
NAPEPLD Q6IQ20 1/20 0.32
AVPR1A P37288 2/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5871146 0.91 CTSD (0.36) CTSDTACR1NPC1FAAHACHE
SCHEMBL5871017 0.84 CTSD (0.37) CTSDYAP1TACR1NPC1NAPEPLD
SCHEMBL5871706 0.71 TACR1 (0.41) TACR1AVPR1AHSD17B10
SCHEMBL4081920 0.69 SCD (0.40) TACR1AVPR1A
SCHEMBL5871281 0.69 TACR1 (0.41) TACR1AVPR1AALDH1A1TSHRHSD17B10
Oxalic Acid SCHEMBL5871679 0.68 CCR3 (0.41) FAAHACHEBCHEKDM4EALDH1A1
SCHEMBL4076932 0.66 HTR1A (0.39) TSHR
SCHEMBL5871795 0.65 CYP2D6 (0.41) KDM4EALDH1A1TSHR
SCHEMBL5871510 0.65 HTR2A (0.37)
SCHEMBL5872132 0.65 KMT2A (0.43) NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071201-B2 Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline EISAI CO., LTD. (JP) 2006-07-04 US disclosed
EP-0976732-B1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES EISAI CO LTD (JP) 2004-11-24 EP disclosed
US-6579881-B2 Indoles EISAI CO., LTD. (JP) 2003-06-17 US disclosed
US-6448243-B1 SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA EISAI CO., LTD. (JP) 2002-09-10 US disclosed
US-20020086999-A1 Certain quinoline derivatives EISAI CO., LTD. 2002-07-04 US disclosed
US-20020019531-A1 Indoles EISAI CO., LTD. 2002-02-14 US disclosed
EP-0976732-A1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019531-A1 Indoles INMT, MUSK, MB CTSD 4082/4885YAP1 4501/4885TACR1 570/4885
US-20020086999-A1 Certain quinoline derivatives CHRM1, CHRNA5, CHRNA4 CTSD 3722/4885YAP1 4788/4885TACR1 693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.